Efficacy plus...Once we get approval and become available as an option to urologists, we want to be the option they prefer to use. The recent interview with Dr. Kulkarni sheds light on why our treatment might be, as Dr. Kamat once wrote, "just what the doctor ordered":
- "early results quite promising...quite good"
- "excellent safety" "quite safe and tolerated procedure"
- "It's a single treatment. So that's very appealing"
- "...it is a urologist run therapy. Urologists are comfortable going to the OR and treating patients cystoscopically or endoscopically"
- "far more practical than a systemic therapy, and it doesn't have any of the systemic side effects of immune checkpoint inhibitors"